CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancerRaymond J. Lim, Bin Liu, Jensen Abascal et al.|Cell Reports Medicine|2024Cited by 111
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway AberrationsThereasa A. Rich, Oliver Gautschi, Victoria M. Raymond et al.|Clinical Cancer Research|2019Cited by 91
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunityRamin Salehi‐Rad, Steven M. Dubinett, Jensen Abascal et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 30
Characteristics of a <i>CCL21</i> Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung CancerMichael S. Oh, Bin Liu, Camelia Dumitras et al.|Molecular Cancer Therapeutics|2024Cited by 10
Abstract CT219: Phase I trial of <i>in situ</i> vaccination with autologous <i>CCL21</i> gene-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced non-small cell lung cancer (NSCLC)Bin Liu, Steven M. Dubinett, Fereidoun Abtin et al.|Cancer Research|2022Cited by 1